The effectiveness of de-escalation to cefmetazole for bacteremia. Open-label randomized non-inferiority trial

The effectiveness of de-escalation to cefmetazole for bacteremia. Open-label randomized non-inferiority trial - De-escalation to cefmetazole

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028155

Enrollment

184

Registered

2017-07-10

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bacteremia

Interventions

de-escalation to cefmetazole 1g every 6-8 hours for about 10-14 days, depending on renal function of the patients. Continues current treatment for about 10-14 days, depending on renal function of the

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Bacteremic patients diagnosed by blood cultures, and those who were judged to be eligible for de-escalation to cefmetazole by infectious diseases doctors.

Exclusion criteria

Exclusion criteria: When the patient or the physician treating did not consent to the study participation. Those who had or are likely to have significant past history of cefmetazole side effects, such as anaphylaxis by beta-lactams.

Design outcomes

Primary

Measure	Time frame
Mortality at 30 days after entry.	—

Countries

Japan

Contacts

Public ContactToko Nakata

Kobe University Division of Infectious Diseases

kobeid@med.kobe-u.ac.jp078-382-6297

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026